Abstract
Alzheimers disease (AD) is a progressive neurodegenerative pathology with severe economic and social impact. There is currently no cure, although cholinesterase inhibitors provide effective temporary relief of symptoms in some patients. Nowadays, drug research and development are based on the cholinergic hypothesis that supports the cognition improvement by regulation of the synthesis and release of acetylcholine in the brain. There are only four commercial medicines approved for treatment of AD, and natural products have played an important alternative role in the research for new acetylcholinesterase inhibitors, as exemplified through the discovery of galantamine. This profile conducts us to give in this paper an overview relating the several classes of natural products with anti-cholinesterasic activity as potential templates to the design of new selective and powerful anti-Alzheimer drugs.
Keywords: neurodegenerative disorder, tau, cholinomimetic therapy, nicotinic agonists, neuroprotection, ginkgo biloba, galantamine, dihydrotanshinone, megislactone
Mini-Reviews in Medicinal Chemistry
Title: New Anti-Alzheimer Drugs from Biodiversity: The Role of the Natural Acetylcholinesterase Inhibitors
Volume: 5 Issue: 10
Author(s): Claudio Viegas Jr., Vanderlan d. S. Bolzani, Eliezer J. Barreiro and Carlos A. Manssour Fraga
Affiliation:
Keywords: neurodegenerative disorder, tau, cholinomimetic therapy, nicotinic agonists, neuroprotection, ginkgo biloba, galantamine, dihydrotanshinone, megislactone
Abstract: Alzheimers disease (AD) is a progressive neurodegenerative pathology with severe economic and social impact. There is currently no cure, although cholinesterase inhibitors provide effective temporary relief of symptoms in some patients. Nowadays, drug research and development are based on the cholinergic hypothesis that supports the cognition improvement by regulation of the synthesis and release of acetylcholine in the brain. There are only four commercial medicines approved for treatment of AD, and natural products have played an important alternative role in the research for new acetylcholinesterase inhibitors, as exemplified through the discovery of galantamine. This profile conducts us to give in this paper an overview relating the several classes of natural products with anti-cholinesterasic activity as potential templates to the design of new selective and powerful anti-Alzheimer drugs.
Export Options
About this article
Cite this article as:
Viegas Jr. Claudio, Bolzani d. S. Vanderlan, Barreiro J. Eliezer and Manssour Fraga A. Carlos, New Anti-Alzheimer Drugs from Biodiversity: The Role of the Natural Acetylcholinesterase Inhibitors, Mini-Reviews in Medicinal Chemistry 2005; 5 (10) . https://dx.doi.org/10.2174/138955705774329546
DOI https://dx.doi.org/10.2174/138955705774329546 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RNA Metabolism in Neurodegenerative Disease
Current Chemical Biology Frontotemporal Lobar Degeneration (FTLD): Review and Update for Clinical Neurologists
Current Alzheimer Research Design and Development of Novel Transdermal Nanoemulgel for Alzheimer’s Disease: Pharmacokinetic, Pharmacodynamic and Biochemical Investigations
Current Drug Delivery Liver Growth Factor as a Tissue Regenerating Factor in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Thematic Issue: Old Facts and New Perspectives to Face Alzheimer’s Dementia. Focus on Non Neuronal Participants to Neurodegeneration)
CNS & Neurological Disorders - Drug Targets Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation
Current Molecular Medicine Aptamers as Innovative Diagnostic and Therapeutic Agents in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Cytokines in Neuroinflammation and Alzheimers Disease
Current Drug Targets Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease
Current Drug Metabolism Lower Frequency of co-Morbid Medical Disorders Related to Poor Impulse Control in Parkinson’s than Alzheimer’s Disease
Current Aging Science <i>In silico</i> and <i>In vivo</i> Evaluation of Oxidative Stress Inhibitors Against Parkinson's Disease using the <i>C. elegans</i> Model
Combinatorial Chemistry & High Throughput Screening Epilepsy, Regulation of Brain Energy Metabolism and Neurotransmission
Current Medicinal Chemistry Synthesis and Biological Activities of Some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide Derivatives
Letters in Drug Design & Discovery Platelet-Activating Factor (PAF) Antagonists Attenuate Inflammatory- Based Pain: Potential Cellular and Anatomical Sites of PAF Action
Central Nervous System Agents in Medicinal Chemistry Differentiating the Dementias. Revisiting Synucleinopathies and Tauopathies
Current Alzheimer Research Multitarget Network Strategies to Influence Memory and Forgetting: The Ras/Mapk Pathway as a Novel Option
Mini-Reviews in Medicinal Chemistry Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design Screening of Early and Late Onset Alzheimer’s Disease Genetic Risk Factors in a Cohort of Dementia Patients from Liguria, Italy
Current Alzheimer Research Subject Index to Volume 4
Current Medicinal Chemistry - Central Nervous System Agents